Statins, the cholesterol‐lowering agents, are well‐tolerated and are known to lower the risk of atherosclerotic cardiovascular diseases. However, if Musculoskeletal Adverse Events ( MAEs ) like myalgia, myopathy, and rhabdomyolysis develop during the statin use period, these agents may need to be temporarily or permanently discontinued. Thus, in order to reduce and prevent the risk of adverse events, it is important to acquire information on both the risk and onset timing of drug-related adverse events.
In this regard, a recent study published in Pharmacology Research And Perspectives evaluated the onset timing of MAEs that develop during statin monotherapy. The study also determined the shifts in onset timing of MAEs when statins are used concomitantly with other drugs. According to the study, the maximum number of cases of MAE onset was associated with atorvastatin, followed by…
